NCT07144072View on ClinicalTrials.gov

Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

January 31, 2028

Study Completion Date

July 31, 2028

Conditions

Frailty in Older Adults

Interventions

DRUG

HeXell-2020

Cohort 1: 5 × 10⁷ cells per dose, administered via IV infusion every 2 weeks for a total of 3 doses Cohort 2 : 5 × 10⁷ cells per dose, administered via IV infusion every 2 weeks for a total of 6 doses